Form D · Biotechnology
GestVision, Inc.
Groton, CT · CIK 0001657762
Offering snapshot reported Jul 6, 2020 · SEC filing
- Reported sold
- $10M Offering amount: $10M
- Investors reported
- 1 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jun 19, 2020 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jul 6, 2020 | Initial | $10,000,000 | No comparison | 1 | SEC filing |
| Nov 30, 2016 | Amendment | $7,106,300 | $5,000,000vs Nov 22, 2016 | 2 | SEC filing |
| Nov 22, 2016 | Initial | $2,106,300 | No comparison | 2 | SEC filing |
Offering details
- Securities
- Debt, Security to be acquired
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-370248
Source: Form D, filed Jul 6, 2020. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Robert D. Auerbach | Director |
| Wendy L Davis | Director, Executive |
| Heiner Dreismann | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
Bioct Innovation Commons 93 Shennecossett Road
Groton, CT, 06340
Groton, CT, 06340